N-acetylcysteine potentiates doxorubicin-induced
ATM and p53 activation in ovarian cancer cells

GABRIELLA BRUM1, THOMAS CARBONE1, ERIC STILL1, VENDITA CORREIA1,
KEVIN SZULAK1, DAVID CALIANESE1, CHARLES BEST1, GARRET CAMMARATA1,
KATELYN HIGGINS1, FANG JI2, WEN DI2 and YINSHENG WAN1

1Department of Biology, Providence College, Providence, RI 02918, USA; 2Department of Obstetrics and
Gynecology, Renji Hospital of Shanghai Jiaotong University Medical School, Shanghai 200001, P.R. China

Received July 16, 2012; Accepted September 7, 2012

DOI: 10.3892/ijo.2012.1680

Abstract. Doxorubicin has been used clinically to treat various
types of cancer, and yet the molecular mode of actions of
doxorubicin remains to be fully unraveled. In this study, we
investigated the effect of doxorubicin on cultured ovarian
cancer cells (CaOV3). MTT assay data showed that doxorubicin
inhibits cell proliferation in a time- and dose-dependent
manner. Phagokinetic cell motility assay data indicated that
doxorubicin inhibits both basal level and EGF-induced cell
migration in CaOV3 cells. Confocal microscopic data revealed
that doxorubicin induces reorganization of cytoskeletal
proteins including actin, tubulin and vimentin. Doxorubicin
induces phosphorylation of p53 at Ser15 and 20, acetylation of
p53 and ATM activation. Doxorubicin also induces phosphory-
lation of histone H2AX at Ser139. Interestingly, doxorubicin
also inhibits mTOR activity, measured by phosphorylation
of S6 ribosomal protein. Pretreatment of CaOV3 cells with
antioxidant N-acetylcysteine (NAC), but not pyrrolidine
dithiocarbamate (PDTC) potentiates doxorubicin-induced
phosphorylation of p53 and ATM. Collectively, we conclude
that doxorubicin induces reorganization of cytoskeletal
networks, inhibition of mTOR activity, and inhibition of cell proliferation and migration. Our data also suggest that removal of oxidants by antioxidants such as NAC may enhance the efficacy of doxorubicin in vivo.

Introduction

Doxorubicin (Dox) is a potent antineoplastic agent used to treat
various types of cancer including ovarian cancer, despite a
cumulative cardiomyopathy that might reduce the therapeutic
index for treatment (1). It has been shown that doxorubicin
causes DNA damage, with a result of cell cycle block or apo-
ptosis (2), while other studies support the notion that different
doses of doxorubicin activate different regulatory mechanisms
to induce either apoptosis or cell death through mitotic catastro-
phe (3).

ATM/p53 pathway is involved in Dox-induced apoptosis. Studies have demonstrated that pretreatment of cells with
the hydroxyl radical scavenger, N-acetylcysteine (NAC) significantly attenuates doxorubicin-mediated phosphory-
lation and accumulation of p53, p53-DNA binding, and the
phosphorylation of H2AX and Cdk4, suggesting that hydroxyl
radicals contribute to the doxorubicin-induced activation of
ATM-dependent pathways (4,5).

Studies have also shown that wortmannin, an inhibitor of
ATM that has high homology with PI3K family and is located
upstream of p53, inhibits activation of Cdk4 without the induc-
tion of p53 in Dox-induced cell death (6). These data suggest
that Cdk4 is one of the essential components for induction of
cell death; p53 may prevent Dox-induced cell death through p21;
and Cdk4 may be activated by ATM, which is necessary for the
activation of p53 in Dox-induced apoptosis (6).

In addition to ATM/p53 pathway activation, accumulating
evidence suggest that Dox activates distinct members of PI3K
family which then activates MAPK/NF-xB cell survival
pathway that opposes the apoptotic response following DNA
damage (7) and may eventually contribute to drug resis-
tance. Abundant studies have demonstrated that activation of
PI3K/AKT pathway leading to mTOR activation with a result
of activation of downstream component such as s6 ribosomal
protein (8). However, the question as to whether Dox has any
effect on mTOR remains to be addressed.

The cytoskeleton plays an important role in many cellular
processes, including mitosis, cytokinesis, intracellular trans-
port, endocytosis and secretion, and it is also involved in the
transcriptional activities of various genes. Induction of cell
death with doxorubicin treatment is has been shown to be
associated with both mitotic catastrophe (at both lower and
higher doxorubicin concentrations) and apoptosis (at higher
doxorubicin concentration). It has been proposed that apoptosis
and mitotic catastrophe are independent from each other (9).
Studies have shown that doxorubicin induces re-distribution of F-actin, vimentin and tubulin (10). The reorganization of cytoskeletal proteins is consistent with features of apoptosis, with an increase in bright staining of F-actin, vimentin and tubulin at the site of apoptotic body formation, suggesting that actin might be involved in the chromatin remodeling during apoptosis (10). However, whether Dox induces cytoskeletal protein reorganization and chromatin remodeling in ovarian cancer cells remains unknown.

Cell migration is regulated by actin and microtubule cytoskeleton in which Rho GTPases are involved. It has been suggested that targeting actin cytoskeleton by cancer drugs may provide a means to prevent metastasis formation (1,11). Our preliminary studies have shown that Dox inhibits ovarian cancer cell migration. However, the question whether Dox-inhibited cell migration is related to cytoskeletal protein reorganization remains to be addressed.

Given that cytoskeletal proteins play important roles in apoptosis and cell migration, we undertook this project to study the effect of doxorubicin on both apoptosis and cell migration via cytoskeletal protein reorganization and ATM/p53 pathway activation. Our data showed that doxorubicin-induced cell death and inhibition of cell migration are associated with cytoskeletal protein reorganization, ATM/p53 activation, and chromatin remodeling. Antioxidant NAC potentiates the effect of doxorubicin in vitro in cultured ovarian cancer cells (CaOV3 cells) and may be applied in vivo studies.

Materials and methods

Chemicals and reagents. Doxorubicin, NAC, pyrrolidine dithiocarbamate (PDTC) and monoclonal mouse anti-β-actin were obtained from Sigma (St. Louis, MO, USA). Wortmannin and Hoechst were from CalbioChem (San Diego, CA, USA). rabbit anti-tubulin, rabbit anti-vimentin, rabbit anti-p-p53, acetylated p53, p-ATM and p-H2AX were from Cell Signaling Technology (Beverly, MA, USA). Alexa Fluor® 488 goat anti-rabbit/mouse IgG (H+L), Alexa Fluor® 680 goat anti-rabbit/mouse IgG (H+L), were from Life Technologies (Grand Island, NY, USA).

Cell culture. Human ovarian cancer CaOV3 cells were maintained in DMEM (Sigma) supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin (1:100, Sigma) and 4 mM L-glutamine, in a CO2 incubator at 37°C.

Cell viability assay (MTT dye assay). Cell viability was measured by the MTT test as previously described (13-15). Briefly, 12-well plates were coated with 20 µg/ml of fibronectin (Sigma) and 2.4 ml of microsphere suspension (86 µl of stock microbead solution in 30 ml of PBS, Sigma) was added to each well. The plates were then centrifuged at 1,200 rpm at 4°C for 20 min and carefully transferred to a CO2 incubator at 37°C for at least 1 h. About 1.8 ml of supernatant was removed from each well and finally 1,500 freshly trypsinized cells in 2 ml of DMEM were seeded in each well. Cells were cultured for 36 h in the presence or absence of the appropriate reagents and then photographed with an inverted microscope with a Carl Zeiss digital camera (SPOT). At least 50 cells in 10 random views from each condition were quantified for the distance that they had migrated.

Confocal microscopy. Cells were plated in 8-well chamber slides (Lab-Tek, Nalge Nunc International, Naperville, IL, USA) and washed in phosphate balanced saline (PBS) to remove traces of medium. The cells were then fixed for 20 min in fresh 4% paraformaldehyde-PBS, permeabilized and blocked with normal goat serum (diluted 1:10) for 2 h in PBS. Cells were then washed three times in PBS and incubated with primary antibody overnight at room temperature, followed by another three times PBS wash and secondary antibody incubation at room temperature for 1 h. The cell nuclei were also stained with Hoechst (1 µg/ml in PBS) for 10 min. The slides were mounted with anti-fade (Life Technologies, Grand Island, NY, USA) and kept in the dark until viewing. The samples were observed under a confocal microscope (Carl Zeiss) and images were captured by Zen 2009 Light Edition.

Results

Doxorubicin induces cell death in cultured ovarian cancer cells. Doxorubicin has been shown to induce cell death in a variety of cancer cells including ovarian cancer cells in vitro (16,17) and clinically applied to various types of cancer (18). Different doses of doxorubicin activate different regulatory mechanisms to induce either apoptosis or cell death through mitotic catastrophe in cancer cells (3). To test the effect of doxorubicin on cell death in cultured ovarian cancer cells, we cultured CaOV3 cells in 96-well plates and treated the cells with various concentrations of doxorubicin or at different time points. The results showed that doxorubicin induces cell death in a time- and dose-dependent manner (Fig. 1A-D).

Doxorubicin inhibits EGF-induced cell migration in cultured ovarian cancer cells. Above data show that doxorubicin inhibits cell proliferation in cultured ovarian cancer cells. Our previous studies have shown that EGF induces cell migration in CaOV3 cells, which is inhibited by EGFR inhibitors and curcumin (19). To test whether Doxorubicin has any effect on cell migration, we used phagokinetic track motility assay. The results showed that doxorubicin inhibits cell migration with or without EGF treatment (Fig. 2).

Doxorubicin induces reorganization of cytoskeletal proteins in CaOV3 cells. The cytoskeleton plays an important role in many cellular processes but also is involved in gene transcription.
Figure 1. Effect of doxorubicin on cell viability in cultured ovarian cancer cells. CaOV3 cells were cultured in 96-well plates and treated with various concentrations of doxorubicin. (A) Cells were observed 24 h after treatment under an inverted microscope and (B) cell viability was measured by MTT assay. Cells were treated with doxorubicin at the concentration of 10 µM and (C) observed at different time points and (D) cell viability was assayed by MTT.
Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility (11). Doxorubicin induces morphological alterations in mitochondrial, nuclear and fibrous protein structures, which are dependent on the drug concentration (20-22). Doxorubicin affects actin assembly \textit{in vitro} (9,23,24). To study the effect of doxorubicin on cytoskeletal proteins, we cultured CaOV3 cells in 8-well chamber slides. The cells were treated with 10 µM of doxorubicin and fixed at various time points, and stained with anti-actin, tubulin and vimentin antibodies. Confocal microscopic data showed that doxorubicin treatment induces reorganization of cytoskeletal proteins (Fig. 3).

NAC potentiates doxorubicin-induced activation of ATM, p53, and histone proteins. ATM/p53 pathway has been reported to be involved in apoptosis of various cancer cells induced by chemotherapy drugs (25). Doxorubicin has been shown to activate ATM and p53, leading to cell death, mediated by reactive oxygen species (4,26,27). Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics (28). Chromosomal breaks during mitotic catastrophe trigger γ-H2AX-ATM-p53-mediated apoptosis (29). Antioxidant NAC has been shown to affect doxorubicin-induced cell death in two distinct ways (30). To test whether NAC has effect on Dox-induced ATM and p53 activation, we treated the cells with NAC (500 µM) for 2 h, then Dox for 2 h. Cells were stained with anti-p-ATM and p-p53. Confocal microscopic data showed that Dox induces ATM and p53 phosphorylation. However, surprisingly, NAC pretreatment enhances ATM and p53 phosphorylation induced by Dox. Neither PTDC nor Wortmannin has such effect (Fig. 4A and B). The results also showed that doxorubicin induces p53 acetylation and H2AX phosphorylation, which is also enhanced by NAC but not PDTC or Wortmannin (Fig. 4C and D).

Discussion

Doxorubicin has been used clinically to treat various types of cancer, and the molecular mechanisms through which doxorubicin acts are still being elucidated. Studies have suggested that induction of cell death with doxorubicin treatment is due to two independent events, namely mitotic catastrophe and apoptosis, depending on the treated dose (9). Our present study shows that in addition to apoptosis induction, doxorubicin also inhibits cell migration in ovarian cancer cell line CaOV3 cells (Figs. 1 and 2).

Studies have been done to investigate the effect of doxorubicin on reorganization of F-actin, vimentin and tubulin during apoptosis (10). The reorganization of cytoskeletal proteins appears to be linked to features of apoptosis. The results that F-actin, vimentin and tubulin are remarkably concentrated at the apoptotic bodies suggest that these cytoskeletal proteins play important roles in this process. In this study, we found that doxorubicin induces cytoskeletal protein reorganization in ovarian cancer CaOV3 cells. This reorganization may contribute to the apoptosis of cells induced by doxorubicin.

It has been shown that cell movement and migration are mainly orchestrated by the actin and microtubule cytoskeleton. Various cytoskeleton modifications are associated with malignant cell transformation and have been used as prognostic
Figure 3. Effect of doxorubicin on cytoskeletal proteins in cultured ovarian cancer cells. CaOV3 cells were cultured in 8-well chamber slides, treated with 10 µM of doxorubicin and fixed at different time points. Tubulin, vimentin and actin filaments were stained with antibodies and visualized under a confocal microscope.
Figure 4. Effect of NAC on doxorubicin-induced activation of ATM, p53 and H2AX in cultured ovarian cancer cells. CaOV3 cells were cultured in 8-well chamber slides, pretreated with NAC, PDTC, or Wortmannin, for 2 h and then treated with doxorubicin. Cells were fixed 2 h post-doxorubicin treatment. Antibodies were used to detect (A) phospho-ATM, (B) phospho-p53, (C) acetylated p53 and (D) phospho-H2AX. Confocal microscopy was performed.
factors. Targeting cytoskeleton network may attenuate metastatic activities of tumor cells (11,31). In addition to actin cytoskeletal proteins, research has suggested that intermediate filament vimentin could be a marker associated with chemoresistance or a marker of malignancy in certain epithelial cancers (32). Changes in vimentin filaments has been reported in dox treated leukemia cells (10,33-35). Vimentin mediate a drug-resistant invasive phenotype in diffuse large B cell lymphoma (36). We found that vimentin is also reorganized in doxorubicin treated CaOV3 cells (Fig. 3).

ATM/p53 pathway has been reported to be involved in apoptosis of various cancer cells induced by chemotherapy drugs (25). Doxorubicin has been shown to activate ATM and p53, leading to cell death (4,26,27). Doxorubicin enhances microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics (28). Chromosomal breaks during mitotic catastrophe induces H2AX-ATM-p53-mediated apoptosis (29). In this study, we observed that doxorubicin induces ATM and p53 phosphorylation (Fig. 4A and B) in CaOV3 cells. Also, our results showed that doxorubicin induces p53 acetylation and H2AX phosphorylation (Fig. 4C and D).

Antioxidant N-acetylcysteine, has been shown to affect doxorubicin-induced cell death in two distinct ways (30). NAC, a pro-glutathione drug, increases the resistance of both cells against doxorubicin. Studies have demonstrated that NAC enhances MRP1-mediated doxorubicin resistance and this effect depends on GSH synthesis (37). It has been shown that doxorubicin induces ATM activation via production of reactive oxygen species and antioxidants, such as NAC, inhibiting doxorubicin-induced ATM activation (4). In this study, we tested whether NAC has any effects on doxorubicin-induced ATM activation in CaOV3 cells. Surprisingly, NAC pretreatment enhances ATM and p53 phosphorylation, p53 acetylation and H2AX phosphorylation (Fig. 4). Interestingly, neither PDTC nor wortmannin has this effect.

Cancer cells including ovarian cancer cells are resistant to chemotherapy drugs such as doxorubicin. It would be beneficial to chemotherapy if such resistance is suppressed. NAC has been shown to protect from doxorubicin-induced hepatotoxicity and cardiotoxicity during chemotherapy (30,38-40). NAC also been shown to enhance drug resistance (37). However, according to our data, NAC may potentiate doxorubicin’s effect in chemotherapy in ovarian cancer. In fact, combinatory therapy with doxorubicin has been becoming more beneficial approach (41,42). Further in vitro and in vivo studies will be necessary to test such possibility.

Acknowledgements

This study was supported partly by a grant from the National Natural Science Foundation of China (no. 30772306, WD) and a grant from NIH (P20 RR016457 from INBRE Program of the National Center for Research Resources, YW).

References

1. Sardao VA, Oliveira PJ, Holy J, Oliveira CR and Wallace KB: Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 25: 227-243, 2009.

2. Hublarova P, Greplova K, Holakova J, Vojtesek B and Hrstka R: Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases. Cell Mol Life Sci 15: 473-484, 2010.

3. Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G and Choi KS: Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24: 65-77, 2005.

4. Kurz EU, Douglas PA and Lees-Miller SP: Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 279: 53272-53281, 2004.

5. Voisard R, Selitzer U, Baur R, Dartsch PC, Osterheus H, Houben M and Homby WC: A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis. Int J Cardiol 51: 15-28, 1995.

6. Otsuka Y, Tanaka T, Uchida D, Noguchi Y, Saeki N, Saito Y and Tatsuno I: Roles of cyclin-dependent kinase 4 and p53 in neuronal cell death induced by doxorubicin on cerebellar granule neurons in mice. Neurosci Lett 365: 180-185, 2004.

7. Panta GR, Kaur S, Cavin LG, Cortes ML, Mercurio F, Lothstein L, Sweatman TW, Israel M and Arsura M: ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase (p90(rsk)) signaling pathway. J Biol Chem 279: 53272-53281, 2004.

8. Wu R, Hu TC, Rehemtulla A, Fearon ER and Cho KR: Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 17: 7159-7172, 2011.

9. Litwiniec A, Grzanka A, Helmin-Basa A, Gackowska L and Grzanka D: Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins. J Cancer Res Clin Oncol 136: 717-736, 2010.

10. Grzanka A, Grzanka D and Orlikowska M: Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. Biochem Pharmacol 66: 1611-1617, 2003.

11. Bijman MN, van Berkel MP, van Nieuw Amerongen GP and Boven E: Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. Biochem Pharmacol 76: 707-716, 2008.

12. Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Wanebo H, Kouttab N, Chu W and Yan Y: Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncol Rep 16: 907-913, 2006.

13. Grzanka A, Grzanka D and Orlikowska M: Roles of cyclin-dependent kinase 2 and CDK4 in the development of chemoresistance in human ovarian cancer cells. J Mol Biol 325: 985-997, 2003.

14. Qiu L, Wang Q, Di W, Jiang Q, Scheffler E, Derby S, Wanebo H, Yan B and Yan Y: Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol 27: 823-830, 2005.

15. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B and Yan Y: Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 27: 1441-1448, 2005.

16. Bagriacik EU, Uslu K, Yurtcu E, Steffeck M and Karasu C: Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells. Cell Biol Int 31: 979-984, 2007.

17. Rogalska A, Gajek A, Szwed M, Jozwiak Z and Marczak A: Histological assessment after direct injection into the sternocleidomastoid muscle. Muscle Nerve 21: 1457-1464, 1998.

18. Albrecht-Buehler G: The phagokinetic tracks of 3T3 cells. Cell 90: 494-497, 1977.

19. Qiu L, Wang Q, Di W, Jiang Q, Scheffler E, Derby S, Wanebo H, Yan B and Yan Y: Transient activation of EGFR/ACTK cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol 27: 823-830, 2005.

20. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B and Yan Y: Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 27: 1441-1448, 2005.

21. Bagriacik EU, Uslu K, Yurtcu E, Steffeck M and Karasu C: Stobadine inhibits doxorubicin-induced apoptosis through a caspase-9 dependent pathway in P815 mastocytoma cells. Cell Biol Int 31: 979-984, 2007.
20. Necco A, Vailati G and Colombo R: Actin behaviour in doxorubicin treatment. Cell Biol Int Rep 7: 129-134, 1983.
21. Dalledonne I, Milzani A and Colombo R: DXR depresses the alpha-actinin-induced formation of actin bundles. Cancer Biochem Biophys 13: 245-254, 1993.
22. Necco A, Usardi C, Scari G, Islam K, Melzner I and Vergani G: The effects of doxorubicin on embryonic spinal motoneurons cultured in vitro: cytoskeletal response. Cytotechnology 11: 133-141, 1993.
23. Colombo R, Necco A, Vailati G, Saracco B, Milzani A and Scari G: Doxorubicin affects actin assembly in vitro. Cell Biol Int Rep 8: 127-135, 1984.
24. Mariano R, Gonzalez B and Lewis W: Cardiac actin interactions with doxorubicin in vitro. Exp Mol Pathol 44: 7-13, 1986.
25. Jaamaa S, Af Hallstrom TM, Sankila A, Rantanen V, Koistinen H, Stenman UH, Yang Z, De Marzo AM, Taari K, Ruutu M, Andersson LC and Laiho M: DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res 70: 8630-8641, 2010.
26. Alexandre J, Hu Y, Lu W, Peliciano H and Huang P: Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67: 3512-3517, 2007.
27. Kim BM, Choi YJ, Lee YH, Joe YA and Hong SH: N,N-Dimethyl phytosphingosine sensitizes HL-60/MX2, a multidrug-resistant variant of HL-60 cells, to doxorubicin-induced cytotoxicity through ROS-mediated release of cytochrome c and AIF. Apoptosis 15: 982-993, 2010.
28. Giannakakou P, Nakano M, Nicolaou KC, O’Brate A, Yu J, Blagosklonny MV, Greber UF and Fojo T: Enhanced microtubule‑dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99: 10855-10860, 2002.
29. Imreh G, Norberg HV, Imreh S and Zhivotovsky B: Chromosomal breaks during mitotic catastrophe trigger gammaH2AX-ATM-p53-mediated apoptosis. J Cell Sci 124: 2951-2963, 2011.
30. Gokcimen A, Kim A, Tola HT, Bayram D, Kocak A, Ozguner F and Ayata A: Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicity. Hum Exp Toxicol 26: 519-525, 2007.
31. Ashley N and Poulton J: Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling. Oncogene 28: 3880-3891, 2009.
32. Bichat F, Mouawad R, Solis-Recendez G, Khayat D and Bastian G: Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 17: 3393-3401, 1997.
33. Grzanka A: Estimation of changes in vimentin filaments induced by etoposide and doxorubicin in human leukemia cell line K-562 by using immunofluorescence microscopy. Neoplasma 48: 285-289, 2001.
34. Grzanka A, Grzanka D and Orlikowska M: Fluorescence and ultrastructural localization of actin distribution patterns in the nucleus of HL-60 and K-562 cell lines treated with cytostatic drugs. Oncol Rep 11: 765-770, 2004.
35. Grzanka D, Marszałek A, Izdebska M, Gackowska L, Andrzej Szczepanski M and Grzanka A: Actin cytoskeleton reorganization correlates with cofillin nuclear expression and ultrastructural changes in cho aa8 cell line after apoptosis and mitotic catastrophe induction by doxorubicin. Ultrastruct Pathol 35: 130-138, 2011.
36. Maxwell SA, Cherry EM and Bayless KJ: Akt, 14-3-3-zeta, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma 52: 849-864, 2011.
37. Akan I, Akan S, Akca H, Savas B and Ozben T: N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance. Eur J Clin Investig 34: 683-689, 2004.
38. Herman EH, Ferrans VJ, Myers CE and Van Vleet JF: Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res 45: 276-281, 1985.
39. Kockar MC, Naziroglu M, Celik O, Tola HT, Bayram D and Koyu A: N-acetylcysteine modulates doxorubicin-induced oxidative stress and antioxidant vitamin concentrations in liver of rats. Cell Biochem Funct 28: 673-677, 2010.
40. Park ES, Kim SD, Lee MH, Lee HS, Lee IS, Sung JK and Yoon YS: Protective effects of N-acetylcysteine and selenium against doxorubicin toxicity in rats. J Vet Sci 4: 129-136, 2003.
41. Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA and Corey SJ: Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 101: 38-47, 2009.
42. Bulucu F, Oktentli C, Kenar L, Koc B, Ocal R, Karadurmus N, Inal V, Yamanli M, Sanisoglu YS and Aydin A: Detrimental effects of N-acetylcysteine plus desferoxamine combination in an experimental nephrotic syndrome model. Int J Toxicol 26: 525-532, 2007.